Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) fell 6.1% during mid-day trading

Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) insider Tobin Juvenal sold 1,034 shares of

Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN)

Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN)

FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a compan

Study data showed more than half of patients who used targeted systemic therapies modified treatment

Study data showed more than half of patients who used targeted systemic therapies modified treatment

New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support gro

New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing

Decision modeling study shows use of TissueCypher can nearly double appropriate escalation of care f

DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk fact

STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investor

The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While em

FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company

FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company

Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during

Castle Biosciences (NASDAQ: CSTL - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) ar

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the pr

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.07 per share versus the Zacks C

Castle Biosciences NASDAQ: CSTL reported second-quarter 2026 revenue of $103.5 million, up 20% from

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $345.000 million-$355.000 million

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.07) per share which beat the analy

FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company

Approval expands access to Castle's precision medicine test designed to guide systemic treatment dec

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurate

Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s

Roth Capital analyst Max Masucci initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Bu

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the pr

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and l

Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $340.000 million-$350.000 million

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.49) per share which met the analys

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologicall

Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and l

Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Me

Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that gui

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and r

Castle Biosciences (NASDAQ:CSTL) sees FY2026 sales of $340.000 million-$350.000 million vs $333.778

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.08) per share which beat the analy

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that gui